Relative strength vs biotech sector average enhances the ADMA stock forecast appeal to fund managers seeking defensive growth within healthcare equities. Since institutional investors own more than half the issued stock, the board will likely have to pay attention to their preferences. We note that hedge funds don't have a meaningful investment in ADMA Biologics. Our data shows that BlackRock, Inc. is the largest shareholder with 16% of shares outstanding. Meanwhile, the second and third largest shareholders, hold 7.1% and 4.8%, of the shares outstanding, respectively. In addition, we found that Adam Grossman, the CEO has 1.1% of the shares allocated to their name. Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest. Investors tracking ADMA stock forecast note support around $6.95, providing a favorable risk-reward setup for swing trades in current market conditions.
